Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial

Asthma treatment guidelines recommend increasing corticosteroid dose to control symptoms and reduce exacerbations. This approach is potentially flawed because symptomatic asthma can occur without corticosteroid responsive type-2 (T2)-driven eosinophilic inflammation, and inappropriately high-dose co...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	The lancet respiratory medicine Ročník 9; číslo 1; s. 57
Hlavní autoři:	Heaney, Liam G, Busby, John, Hanratty, Catherine E, Djukanovic, Ratko, Woodcock, Ashley, Walker, Samantha M, Hardman, Timothy C, Arron, Joseph R, Choy, David F, Bradding, Peter, Brightling, Christopher E, Chaudhuri, Rekha, Cowan, Douglas C, Mansur, Adel H, Fowler, Stephen J, Niven, Robert M, Howarth, Peter H, Lordan, James L, Menzies-Gow, Andrew, Harrison, Tim W, Robinson, Douglas S, Holweg, Cecile T J, Matthews, John G, Pavord, Ian D
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England 01.01.2021
Témata:	Acute Disease Adrenal Cortex Hormones - administration & dosage Adrenal Cortex Hormones - adverse effects Adrenal Cortex Hormones - therapeutic use Algorithms Anti-Asthmatic Agents - administration & dosage Anti-Asthmatic Agents - adverse effects Anti-Asthmatic Agents - therapeutic use Asthma - drug therapy Biomarkers - blood Cell Adhesion Molecules - blood Drug Dosage Calculations Eosinophils Female Humans Leukocyte Count Male Middle Aged Nitric Oxide - metabolism Risk Factors Single-Blind Method
ISSN:	2213-2619, 2213-2619
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!